FierceBiotechOriginal article
{"a":[{"_":"‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug","$":{"href":"/biotech/novo-backed-claris-bio-emerges-118m-and-eye-rare-corneal-disease","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Novo Holdings-backed Claris Biotech completed a $118 million Series B funding round to develop a corneal disease treatment. The company aims to address a large market opportunity in corneal diseases.
Importance:6/10
Sentiment:
0.70
Series Bcorneal diseaseophthalmologycapital raiserare disease
Read the original article
Published by FierceBiotech on July 27, 2026 5:48 PM
